ClinicalTrials.gg
Active, not recruitingNCT06891222SCANUpdated Jun 8, 2026

A Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening

An observational study in Cardiac Disease, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Mayo Clinic · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,705
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Heart Diseases by Mayo Clinic — 3 open to participants now, 4 under way, none of them phase 3. Heart Diseases · Mayo Clinic.

Started
2025
the only one that year
Observational
14 of 22
1 open now
Registered
20th of 22
by date

Among the 22 studies in Heart Diseases by Mayo Clinic, this one is the only one that started in 2025, is one of 14 observational ones, and was the 20th registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

3 of the 22 studies in Heart Diseases by Mayo Clinic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Heart Diseases by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate and compare the effectiveness of active screening for SHD in asymptomatic outpatients referred for an ECG, using a combination of AI-ECG and FOCUS. Invites will be sent and participants enrolled electronically.

03

Conditions studied

  • Cardiac Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

All subjects aged 18 or older without known congenital or acquired SHD scheduled to undergo an elective outpatient electrocardiogram

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (>18 years of age)
  • Echocardiogram is not clinically indicated

Exclusion criteria

Exclusion Criteria:

  • Prior history of congenital or acquired SHD, as defined by the following

    1. Aortic Stenosis:
    2. Heart Failure
    3. Left Ventricular Dysfunction
    4. Cardiac Amyloidosis
    5. Hypertrophic Cardiomyopathy (HCM)
    6. Rheumatic Heart Disease
    7. Congenital Heart Disease
  • Recent (within last 12 months) echocardiogram
  • Scheduled clinically indicated future echocardiogram
  • Inability to provide to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,705 participants (actual)
Patient registry
No

Groups and cohorts

  • Integrated pathway

    Diagnostic Test: AI-ECG (artificial intelligence-enabled electrocardiogram) · Diagnostic Test: Focus Screening (focused cardiac ultrasonography)

  • Standard of Care pathway

Interventions

  • Diagnostic testAI-ECG (artificial intelligence-enabled electrocardiogram)

    Participants will undergo electrocardiogram analysis using AI-ECG during the baseline visit

  • Diagnostic testFocus Screening (focused cardiac ultrasonography)

    Participants will undergo a focused cardiac ultrasound if the AI-ECG reflects a positive value

06

What researchers measure

Primary outcomes

  1. Percentage of subjects to be diagnosed with SHD (structural heart disease)

    Percentage of subjects to be diagnosed with SHD will be determined by the number of subjects that have a positive SHD screening. Positive SHD screening is defined by any one of the following: decreased LVEF (left ventricular ejection fraction), cardiac amyloidosis, aortic stenosis, and hypertrophic cardiomyopathy.

    Time frame: Baseline, 6 months, 1 year

  2. Positive predictive value (PPV)

    Positive predictive value (PPV) will be measured as a percentage. PPV will reflect the percentage of times that each screening pathway matches a formal echocardiogram diagnosis.

    Time frame: Baseline, 6 months, 1 year

Secondary outcomes

  1. Number of deaths

    Number of deaths will include all-cause deaths.

    Time frame: 1 year

  2. Number of adverse cardiovascular events

    Number of adverse cardiovascular events includes systolic heart failure, rt failure hospitalization.

    Time frame: 1 year

  3. Percentage of subjects to be diagnosed with decreased LVEF (left ventricular ejection fraction)

    Percentage of subjects to be diagnosed with decreased LVEF will be determined by the percentage of subjects to have a LVEF lower than 50%.

    Time frame: Baseline, 6 months,1 year

  4. Percentage of subjects to be diagnosed with cardiac amyloidosis

    Percentage of subjects to be diagnosed with cardiac amyloidosis will be determined by the number of subjects that have a positive AI-ECG or ultrasound. Cardiac amyloidosis is the buildup of protein in the heart muscle that affect the structure and function of the heart.

    Time frame: Baseline, 6 months,1 year

  5. Percentage of subjects to be diagnosed with aortic stenosis

    Percentage of subjects to be diagnosed with aortic stenosis will be determined by the number of subjects that have a positive AI-ECG or ultrasound. Aortic stenosis is the narrowing of the aortic value decreasing the blood flow from heart to the aorta.

    Time frame: Baseline, 6 months,1 year

  6. Percentage of subjects to be diagnosed with hypertrophic cardiomyopathy

    Percentage of subjects to be diagnosed with hypertrophic cardiomyopathy will be determined by the number of subjects that have a positive AI-ECG or ultrasound. Hypertrophic cardiomyopathy is the thickening of the heart muscle which leads to reduced blood flow.

    Time frame: Baseline, 6 months,1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Nov 2026, 19 months after the start.

Of 185 non-industry observational studies under Heart Diseases, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 19 months is below that.

Counting every sponsor, half of 239 studies reached it within 46 months; a quarter within 18 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 24, 2025
StartActual
Apr 14, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06891222
Lead sponsor
Mayo Clinic
Responsible party
Gal Tsaban (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Mar 24, 2025
Start date
Apr 14, 2025
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 8, 2026

Study contacts

Gal Tsaban, M.D., Ph.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion